264 related articles for article (PubMed ID: 28408531)
1.
Fendler WP; Calais J; Allen-Auerbach M; Bluemel C; Eberhardt N; Emmett L; Gupta P; Hartenbach M; Hope TA; Okamoto S; Pfob CH; Pöppel TD; Rischpler C; Schwarzenböck S; Stebner V; Unterrainer M; Zacho HD; Maurer T; Gratzke C; Crispin A; Czernin J; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1617-1623. PubMed ID: 28408531
[TBL] [Abstract][Full Text] [Related]
2. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria.
Demirci E; Akyel R; Caner B; Alan-Selçuk N; Güven-Meşe Ş; Ocak M; Kabasakal L
Nucl Med Commun; 2020 Aug; 41(8):759-767. PubMed ID: 32453205
[TBL] [Abstract][Full Text] [Related]
3.
Mei R; Kessler L; Pabst KM; Weber M; Schmidkonz C; Rischpler C; Zacho HD; Hope T; Schwarzenböck SM; Allen-Auerbach M; Emmett L; Ferdinandus J; Unterrainer M; Schaarschmidt BM; Umutlu L; Farolfi A; Castellucci P; Nanni C; Telo S; Fanti S; Herrmann K; Fendler WP
J Nucl Med; 2023 Jul; 64(7):1043-1048. PubMed ID: 37230530
[No Abstract] [Full Text] [Related]
4. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
[TBL] [Abstract][Full Text] [Related]
5.
Basha MAA; Hamed MAG; Hussein O; El-Diasty T; Abdelkhalek YI; Hussein YO; Alasamer AF; Mohamed HAE; Deen DSE; Tantawy EF; Metwally MI; Zaitoun MMA; Aly SA; Altohamy JI; Mohamed AEM; Afifi AHM; Harb O
Abdom Radiol (NY); 2019 Jul; 44(7):2545-2556. PubMed ID: 30963182
[TBL] [Abstract][Full Text] [Related]
6.
Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
[No Abstract] [Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
9. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
10. Interobserver variability, detection rate, and lesion patterns of
Miksch J; Bottke D; Krohn T; Thamm R; Bartkowiak D; Solbach C; Bolenz C; Beer M; Wiegel T; Beer AJ; Prasad V
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2339-2347. PubMed ID: 32157427
[TBL] [Abstract][Full Text] [Related]
11.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
12. Intraobserver and interobserver agreement for the interpretation of 68Ga-prostate-specific membrane antigen-I&T positron emission tomography/computed tomography imaging.
Gültekin A; Yaylalı O; Şengöz T; Yüksel D; Şahin B
Nucl Med Commun; 2019 Dec; 40(12):1250-1255. PubMed ID: 31584465
[TBL] [Abstract][Full Text] [Related]
13. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-PSMA-I&T-PET/CT interobserver and intraobserver agreement for prostate cancer: a lesion based and subregional comparison study among observers with different levels of experience.
Soyluoglu S; Korkmaz U; Ozdemir B; Ustun F; Durmus-Altun G
Nucl Med Commun; 2021 Oct; 42(10):1122-1129. PubMed ID: 34001829
[TBL] [Abstract][Full Text] [Related]
15.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
16.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
17.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
18.
Iravani A; Hofman MS; Mulcahy T; Williams S; Murphy D; Parameswaran BK; Hicks RJ
Cancer Imaging; 2017 Dec; 17(1):31. PubMed ID: 29268784
[TBL] [Abstract][Full Text] [Related]
19.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
20. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
